Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia.
High growth potential with mediocre balance sheet.
Share Price & News
How has Athenex's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2MT's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 2MT exceeded the German Biotechs industry which returned 5.5% over the past year.
Return vs Market: 2MT exceeded the German Market which returned 8.3% over the past year.
Price Volatility Vs. Market
How volatile is Athenex's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Athenex undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 2MT (€12.6) is trading below our estimate of fair value (€51.7)
Significantly Below Fair Value: 2MT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 2MT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 2MT is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2MT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2MT is overvalued based on its PB Ratio (6.8x) compared to the DE Biotechs industry average (3.5x).
How is Athenex forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2MT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: 2MT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 2MT's is expected to become profitable in the next 3 years.
Revenue vs Market: 2MT's revenue (39.6% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: 2MT's revenue (39.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2MT is forecast to be unprofitable in 3 years.
How has Athenex performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2MT is currently unprofitable.
Growing Profit Margin: 2MT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 2MT is unprofitable, and losses have increased over the past 5 years at a rate of -21.4% per year.
Accelerating Growth: Unable to compare 2MT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2MT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 2MT has a negative Return on Equity (-96.63%), as it is currently unprofitable.
How is Athenex's financial position?
Financial Position Analysis
Short Term Liabilities: 2MT's short term assets ($213.5M) exceed its short term liabilities ($90.0M).
Long Term Liabilities: 2MT's short term assets ($213.5M) exceed its long term liabilities ($62.8M).
Debt to Equity History and Analysis
Debt Level: 2MT's debt to equity ratio (39.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 2MT's debt to equity ratio has reduced over the past 5 years.
Inventory Level: 2MT has a low level of unsold assets or inventory.
Debt Coverage by Assets: 2MT's debt is covered by short term assets (assets are 4x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2MT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 2MT has less than a year of cash runway if free cash flow continues to reduce at historical rates of -30.2% each year
What is Athenex's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2MT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 2MT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2MT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2MT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2MT's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Johnson Lau (59yo)
Dr. Yiu-Nam Lau, also known as Johnson, MBBS, MD, FRCP, Ph.D., has been the Chief Executive Officer of Athenex, Inc. since 2011. Dr. Lau is the Vice Chairman and CEO of Axis Therapeutics. Dr. Lau serves as ...
CEO Compensation Analysis
Compensation vs Market: Johnson's total compensation ($USD3.18M) is above average for companies of similar size in the German market ($USD1.31M).
Compensation vs Earnings: Johnson's compensation has been consistent with company performance over the past year.
|Chairman & CEO||9.1yrs||US$3.18m||4.21% $42.0m|
|COO & President of Athenex Pharmaceutical Division||3yrs||US$1.67m||0.27% $2.7m|
|Executive VP & Chief Medical Officer||6.1yrs||US$1.67m||0.17% $1.7m|
|Strategic & Business Advisor||1.9yrs||US$11.00k||no data|
|Co-Founder & President Emeritus||9.1yrs||no data||no data|
|Chief Financial Officer||1.5yrs||no data||0.0052% $51.6k|
|Senior Vice President of Administration & Legal Affairs||1.2yrs||no data||no data|
|Director of Corporate Development & Investor Relations||0yrs||no data||no data|
|Senior Director of Corporate Development||1.1yrs||no data||no data|
|Vice President of Human Resources||0yrs||no data||no data|
Experienced Management: 2MT's management team is considered experienced (2.5 years average tenure).
|Chairman & CEO||9.1yrs||US$3.18m||4.21% $42.0m|
|Independent Director||0.8yrs||no data||no data|
|Independent Director||0.8yrs||no data||no data|
|Independent Director||12.8yrs||US$198.57k||0.48% $4.8m|
|Independent Director||0.8yrs||no data||0.0054% $54.0k|
|Lead Independent Director||3.2yrs||US$216.26k||no data|
|Independent Director||0.8yrs||no data||0.013% $128.9k|
Experienced Board: 2MT's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 2MT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14%.
Athenex, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Athenex, Inc.
- Ticker: 2MT
- Exchange: DB
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.083b
- Listing Market Cap: US$997.411m
- Shares outstanding: 77.38m
- Website: https://www.athenex.com
Number of Employees
- Athenex, Inc.
- Conventus Building
- Suite 600
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ATNX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jun 2017|
|2MT||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2017|
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company’s Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and oral eribulin, an intravenous anticancer drug to treat certain patients with breast cancer and advanced liposarcoma. In addition, the company offers Src Kinase product candidates comprising KX2-391 ointments for actinic keratosis, skin cancers, and psoriasis; KX-01 oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/24 22:57|
|End of Day Share Price||2020/02/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.